Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease

NCT03543540 is registered in ClinicalTrials.gov with ImmusanT, Inc. as lead sponsor.

NCT NCT03543540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03543540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease
Lead sponsor
ImmusanT, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2018
Completion date
September 10, 2018
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease, coeliac disease, digestive system diseases, gastrointestinal disease, gluten sensitivity, intestinal disease, malabsorption syndromes, metabolic disease